A Randomized, Controlled Trial of Ebola Virus Disease Therapeutics.

ABSTRACT:

Background

Although several experimental therapeutics for Ebola virus disease (EVD) have been developed, the safety and efficacy of the most promising therapies need to be assessed in the context of a randomized, controlled trial.

Methods

We conducted a trial of four investigational therapies for EVD in the Democratic Republic of Congo, where an outbreak began in August 2018. Patients of any age who had a positive result for Ebola virus RNA on reverse-transcriptase-polymerase-chain-reaction assay were enrolled. All patients received standard care and were randomly assigned in a 1:1:1:1 ratio to intravenous administration of the triple monoclonal antibody ZMapp (the control group), the antiviral agent remdesivir, the single monoclonal antibody MAb114, or the triple monoclonal

SUBMITTER: Mulangu S 

PROVIDER: S-EPMC10680050 | biostudies-literature | 2019 Dec

REPOSITORIES: biostudies-literature